Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More
Wockhardt is one of the leading domestic pharmaceutical companies with strong presence in the lifestyle segment and a growing focus on biotechnology. While the company made a string of acquisitions in the past namely 'Esparma GmbH' in Germany, 'Pinew... More
GLENMARK PHARMA | WOCKHARDT | GLENMARK PHARMA/ WOCKHARDT |
|||
---|---|---|---|---|---|
P/E (TTM) | x | 11.4 | -12.1 | - | View Chart |
P/BV | x | 1.6 | 0.9 | 173.9% | View Chart |
Dividend Yield | % | 0.6 | 0.0 | 15,008.5% |
![]() ![]() |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
GLENMARK PHARMA Mar-19 |
WOCKHARDT Mar-18 |
GLENMARK PHARMA/ WOCKHARDT |
5-Yr Chart Click to enlarge
|
||
High | Rs | 712 | 1,012 | 70.3% | |
Low | Rs | 484 | 532 | 91.0% | |
Sales per share (Unadj.) | Rs | 349.6 | 355.9 | 98.2% | |
Earnings per share (Unadj.) | Rs | 32.8 | -60.3 | -54.4% | |
Cash flow per share (Unadj.) | Rs | 44.3 | -46.8 | -94.8% | |
Dividends per share (Unadj.) | Rs | 2.00 | 0.01 | 20,000.0% | |
Dividend yield (eoy) | % | 0.3 | 0 | 25,828.3% | |
Book value per share (Unadj.) | Rs | 198.6 | 257.8 | 77.1% | |
Shares outstanding (eoy) | m | 282.17 | 110.63 | 255.1% | |
Bonus/Rights/Conversions | - | - | - | ||
Price / Sales ratio | x | 1.7 | 2.2 | 78.8% | |
Avg P/E ratio | x | 18.2 | -12.8 | -142.4% | |
P/CF ratio (eoy) | x | 13.5 | -16.5 | -81.7% | |
Price / Book Value ratio | x | 3.0 | 3.0 | 100.5% | |
Dividend payout | % | 6.1 | 0 | -36,775.5% | |
Avg Mkt Cap | Rs m | 168,625 | 85,379 | 197.5% | |
No. of employees | `000 | 12.0 | 6.3 | 192.5% | |
Total wages/salary | Rs m | 20,561 | 9,371 | 219.4% | |
Avg. sales/employee | Rs Th | 8,196.0 | 6,295.0 | 130.2% | |
Avg. wages/employee | Rs Th | 1,708.1 | 1,498.3 | 114.0% | |
Avg. net profit/employee | Rs Th | 768.5 | -1,066.3 | -72.1% |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 98,655 | 39,369 | 250.6% | |
Other income | Rs m | 2,081 | 1,202 | 173.1% | |
Total revenues | Rs m | 100,736 | 40,571 | 248.3% | |
Gross profit | Rs m | 15,858 | 18 | 86,656.4% | |
Depreciation | Rs m | 3,259 | 1,495 | 218.0% | |
Interest | Rs m | 3,346 | 2,555 | 131.0% | |
Profit before tax | Rs m | 11,335 | -2,830 | -400.6% | |
Minority Interest | Rs m | 0 | 0 | - | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 1,672 | -3,582 | -46.7% | |
Tax | Rs m | 3,756 | 257 | 1,461.6% | |
Profit after tax | Rs m | 9,250 | -6,669 | -138.7% | |
Gross profit margin | % | 16.1 | 0 | 34,581.0% | |
Effective tax rate | % | 33.1 | -9.1 | -364.9% | |
Net profit margin | % | 9.4 | -16.9 | -55.4% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 66,968 | 33,796 | 198.2% | |
Current liabilities | Rs m | 40,211 | 26,917 | 149.4% | |
Net working cap to sales | % | 27.1 | 17.5 | 155.2% | |
Current ratio | x | 1.7 | 1.3 | 132.6% | |
Inventory Days | Days | 83 | 79 | 105.0% | |
Debtors Days | Days | 81 | 89 | 91.0% | |
Net fixed assets | Rs m | 33,322 | 39,664 | 84.0% | |
Share capital | Rs m | 282 | 553 | 51.0% | |
"Free" reserves | Rs m | 55,770 | 27,968 | 199.4% | |
Net worth | Rs m | 56,052 | 28,522 | 196.5% | |
Long term debt | Rs m | 35,738 | 21,731 | 164.5% | |
Total assets | Rs m | 132,888 | 81,620 | 162.8% | |
Interest coverage | x | 4.4 | -0.1 | -4,080.8% | |
Debt to equity ratio | x | 0.6 | 0.8 | 83.7% | |
Sales to assets ratio | x | 0.7 | 0.5 | 153.9% | |
Return on assets | % | 9.5 | -5.0 | -188.1% | |
Return on equity | % | 16.5 | -23.4 | -70.6% | |
Return on capital | % | 17.8 | -7.7 | -232.1% | |
Exports to sales | % | 0 | 0 | - | |
Imports to sales | % | 0 | 0 | - | |
Exports (fob) | Rs m | NA | NA | - | |
Imports (cif) | Rs m | NA | NA | - | |
Fx inflow | Rs m | 62,998 | 9,807 | 642.4% | |
Fx outflow | Rs m | 22,859 | 1,789 | 1,278.0% | |
Net fx | Rs m | 40,140 | 8,019 | 500.6% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 13,242 | 684 | 1,934.8% | |
From Investments | Rs m | -6,990 | 6,302 | -110.9% | |
From Financial Activity | Rs m | -7,387 | -7,695 | 96.0% | |
Net Cashflow | Rs m | -2,971 | -664 | 447.4% |
Indian Promoters | % | 48.3 | 74.5 | 64.8% | |
Foreign collaborators | % | 0.0 | 0.0 | - | |
Indian inst/Mut Fund | % | 6.9 | 2.3 | 300.0% | |
FIIs | % | 34.4 | 7.7 | 446.8% | |
ADR/GDR | % | 0.0 | 0.1 | - | |
Free float | % | 10.5 | 15.4 | 68.2% | |
Shareholders | 56,727 | 67,757 | 83.7% | ||
Pledged promoter(s) holding | % | 0.0 | 0.0 | - |
Compare GLENMARK PHARMA With: J.B.CHEMICALS ALEMBIC LTD WYETH LTD AJANTA PHARMA SUVEN LIFESCIENCES
Compare GLENMARK PHARMA With: ACTAVIS (US) MYLAN (US) ADCOCK INGRAM (S. Africa) TEVA PHARMA (Israel)
| |
In addition to the usual stock market updates of the week, I talk about how RBI's monetary policy decision and slowing economy impacts you and your portfolio of stocks.
Here's an analysis of the annual report of GLENMARK PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of GLENMARK PHARMA. Also includes updates on the valuation of GLENMARK PHARMA.
For the quarter ended June 2019, WOCKHARDT has posted a net profit of Rs 369 m (up 57.2% YoY). Sales on the other hand came in at Rs 9 bn (down 14.3% YoY). Read on for a complete analysis of WOCKHARDT's quarterly results.
For the quarter ended June 2019, GLENMARK PHARMA has posted a net profit of Rs 1 bn (down 53.1% YoY). Sales on the other hand came in at Rs 23 bn (up 7.3% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.
For the quarter ended March 2019, GLENMARK PHARMA has posted a net profit of Rs 2 bn (up 6.6% YoY). Sales on the other hand came in at Rs 26 bn (up 12.4% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.
For the quarter ended March 2019, WOCKHARDT has posted a net profit of Rs 139 m (up 90.8% YoY). Sales on the other hand came in at Rs 10 bn (down 3.8% YoY). Read on for a complete analysis of WOCKHARDT's quarterly results.
More Views on NewsA single stock - Coca Cola, made Buffett billions. Here's your chance to break into the crorepati club with a single smallcap stock investment.
This one trade had my subscribers laughing all the way to the bank.
Should you invest in growth stocks or value stocks to make strong returns in this market?
The two trends that are playing out as Sensex touches new record high.
Vijay and I have decided to team up and bring you a unique offering never seen before in the Indian stock markets.
More